Cargando…

Blood Peptidome-Degradome Profile of Breast Cancer

BACKGROUND: Cancer invasion and metastasis are closely associated with activities within the degradome; however, little is known about whether these activities can be detected in the blood of cancer patients. METHODOLOGY AND PRINCIPAL FINDINGS: The peptidome-degradome profiles of pooled blood plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yufeng, Tolić, Nikola, Liu, Tao, Zhao, Rui, Petritis, Brianne O., Gritsenko, Marina A., Camp, David G., Moore, Ronald J., Purvine, Samuel O., Esteva, Francisco J., Smith, Richard D.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956627/
https://www.ncbi.nlm.nih.gov/pubmed/20976186
http://dx.doi.org/10.1371/journal.pone.0013133
_version_ 1782188163878354944
author Shen, Yufeng
Tolić, Nikola
Liu, Tao
Zhao, Rui
Petritis, Brianne O.
Gritsenko, Marina A.
Camp, David G.
Moore, Ronald J.
Purvine, Samuel O.
Esteva, Francisco J.
Smith, Richard D.
author_facet Shen, Yufeng
Tolić, Nikola
Liu, Tao
Zhao, Rui
Petritis, Brianne O.
Gritsenko, Marina A.
Camp, David G.
Moore, Ronald J.
Purvine, Samuel O.
Esteva, Francisco J.
Smith, Richard D.
author_sort Shen, Yufeng
collection PubMed
description BACKGROUND: Cancer invasion and metastasis are closely associated with activities within the degradome; however, little is known about whether these activities can be detected in the blood of cancer patients. METHODOLOGY AND PRINCIPAL FINDINGS: The peptidome-degradome profiles of pooled blood plasma sampled from 15 breast cancer patients (BCP) and age, race, and menopausal status matched control healthy persons (HP) were globally characterized using advanced comprehensive separations combined with tandem Fourier transform mass spectrometry and new data analysis approaches that facilitated top-down peptidomic analysis. The BCP pool displayed 71 degradome protein substrates that encompassed 839 distinct peptidome peptides. In contrast, the HP 50 degradome substrates found encompassed 425 peptides. We find that the ratios of the peptidome peptide relative abundances can vary as much as >4000 fold between BCP and HP. The experimental results also show differential degradation of substrates in the BCP sample in their functional domains, including the proteolytic and inhibitory sites of the plasmin-antiplasmin and thrombin-antithrombin systems, the main chains of the extracellular matrix protection proteins, the excessive degradation of innate immune system key convertases and membrane attack complex components, as well as several other cancer suppressor proteins. CONCLUSIONS: Degradomics-peptidomics profiling of blood plasma is highly sensitive to changes not evidenced by conventional bottom-up proteomics and potentially provides unique signatures of possible diagnostic utility.
format Text
id pubmed-2956627
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29566272010-10-25 Blood Peptidome-Degradome Profile of Breast Cancer Shen, Yufeng Tolić, Nikola Liu, Tao Zhao, Rui Petritis, Brianne O. Gritsenko, Marina A. Camp, David G. Moore, Ronald J. Purvine, Samuel O. Esteva, Francisco J. Smith, Richard D. PLoS One Research Article BACKGROUND: Cancer invasion and metastasis are closely associated with activities within the degradome; however, little is known about whether these activities can be detected in the blood of cancer patients. METHODOLOGY AND PRINCIPAL FINDINGS: The peptidome-degradome profiles of pooled blood plasma sampled from 15 breast cancer patients (BCP) and age, race, and menopausal status matched control healthy persons (HP) were globally characterized using advanced comprehensive separations combined with tandem Fourier transform mass spectrometry and new data analysis approaches that facilitated top-down peptidomic analysis. The BCP pool displayed 71 degradome protein substrates that encompassed 839 distinct peptidome peptides. In contrast, the HP 50 degradome substrates found encompassed 425 peptides. We find that the ratios of the peptidome peptide relative abundances can vary as much as >4000 fold between BCP and HP. The experimental results also show differential degradation of substrates in the BCP sample in their functional domains, including the proteolytic and inhibitory sites of the plasmin-antiplasmin and thrombin-antithrombin systems, the main chains of the extracellular matrix protection proteins, the excessive degradation of innate immune system key convertases and membrane attack complex components, as well as several other cancer suppressor proteins. CONCLUSIONS: Degradomics-peptidomics profiling of blood plasma is highly sensitive to changes not evidenced by conventional bottom-up proteomics and potentially provides unique signatures of possible diagnostic utility. Public Library of Science 2010-10-18 /pmc/articles/PMC2956627/ /pubmed/20976186 http://dx.doi.org/10.1371/journal.pone.0013133 Text en Shen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Shen, Yufeng
Tolić, Nikola
Liu, Tao
Zhao, Rui
Petritis, Brianne O.
Gritsenko, Marina A.
Camp, David G.
Moore, Ronald J.
Purvine, Samuel O.
Esteva, Francisco J.
Smith, Richard D.
Blood Peptidome-Degradome Profile of Breast Cancer
title Blood Peptidome-Degradome Profile of Breast Cancer
title_full Blood Peptidome-Degradome Profile of Breast Cancer
title_fullStr Blood Peptidome-Degradome Profile of Breast Cancer
title_full_unstemmed Blood Peptidome-Degradome Profile of Breast Cancer
title_short Blood Peptidome-Degradome Profile of Breast Cancer
title_sort blood peptidome-degradome profile of breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956627/
https://www.ncbi.nlm.nih.gov/pubmed/20976186
http://dx.doi.org/10.1371/journal.pone.0013133
work_keys_str_mv AT shenyufeng bloodpeptidomedegradomeprofileofbreastcancer
AT tolicnikola bloodpeptidomedegradomeprofileofbreastcancer
AT liutao bloodpeptidomedegradomeprofileofbreastcancer
AT zhaorui bloodpeptidomedegradomeprofileofbreastcancer
AT petritisbrianneo bloodpeptidomedegradomeprofileofbreastcancer
AT gritsenkomarinaa bloodpeptidomedegradomeprofileofbreastcancer
AT campdavidg bloodpeptidomedegradomeprofileofbreastcancer
AT mooreronaldj bloodpeptidomedegradomeprofileofbreastcancer
AT purvinesamuelo bloodpeptidomedegradomeprofileofbreastcancer
AT estevafranciscoj bloodpeptidomedegradomeprofileofbreastcancer
AT smithrichardd bloodpeptidomedegradomeprofileofbreastcancer